Lixisenatide is a well-tolerated GLP-1R agonist that can be administered by injection once-daily
Pain and Physical Function Improvements TRIUMPH-4's co-primary endpoint focused on knee osteoarthritis pain, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale: WOMAC Pain Score Reductions: Retatrutide 9mg: -4.5 points (75.8% reduction) Retatrutide 12mg: -4.4 points (73.3% reduction) Placebo: -2.4 points (40.3% reduction) Participants also experienced substantial improvements in physical function, with WOMAC physical function subscale scores improving by: Retatrutide 9mg: -4.1 points Retatrutide 12mg: -4.2 points Placebo: -2.1 points Perhaps most remarkably, a post-hoc analysis revealed that 14.1% of participants on 9mg and 12.0% on 12mg became completely pain-free at 68 weeks, compared to just 4.2% on placebo

Deep Vein Thrombosis (DVT) and Blood Clot Risks A groundbreaking 2021 study published in the Endocrine Journal revealed that Ozempic users face a staggering 266% increased risk of developing deep vein thrombosis compared to patients on other diabetes medications, yet no warnings about blood clot risks appear on the drugs label
It drives normal processes stomach acid, immune responses, alertness but it needs to be broken down promptly
In clinical settings, GHK-Cu formulations are used in dermatologic and aesthetic surgery to optimize post-procedure healing